A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

  • days left to enroll
  • participants needed
  • sponsor
    Lumosa Therapeutics Co., Ltd.
Updated on 28 March 2021


This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy subjects.


This study is a two-part study. Part A is double-blind, placebo-controlled, and will examine the safety and PK profiles of multiple doses of LT3001 drug product in healthy subjects. Part B is open-label and will assess the safety and PK of LT3001 when coadministered with aspirin, clopidogrel, apixaban or dabigatran.

Condition Acute Ischemic Stroke
Treatment Clopidogrel, Placebo, Aspirin, Apixaban, Dabigatran, LT3001 Drug Product
Clinical Study IdentifierNCT04809818
SponsorLumosa Therapeutics Co., Ltd.
Last Modified on28 March 2021


Yes No Not Sure

Inclusion Criteria

Subject's body weight is 50 kg and BMI is within the range of 18 to 32
Subject is a healthy volunteer
Subject's PT, aPTT, and TT are within the normal laboratory range
Subject is a nonsmoker

Exclusion Criteria

Subject has a current or recent history of regular alcohol consumption
Subjects who are enrolled in Part B and allergic to acetylsalicylic acid, other salicylates, clopidogrel, thienopyridines (eg, ticlopidine, prasugrel), apixaban or dabigatran
Part B Cohort 2 only: subjects who are poor metabolizers of clopidogrel (CYP2C19 _2/_ 2, _2/_ 3, or _3/_ 3 genotype)
Subject has a presence or history of coagulation abnormality
Subjects need to receive a surgery or clinical procedures associated with high bleeding risk
Subject has a history of minor bleeding episodes, eg, epistaxis, rectal bleeding, gingival bleeding
Subject has a history of peptic ulcer or gastrointestinal bleeding
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note